Afatinib for the treatment of non-small cell lung cancer

Federica Biello, Claudia Maggioni, Erika Rijavec, Carlo Genova, Giulia Barletta, Elisa Gualco, Anna Truini, Simona Coco, Maria Giovanna Dal Bello, Irene Vanni, Angela Alama, Francesco Boccardo, Francesco Grossi

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Tyrosine kinase inhibitors (TKI) are currently the most effective therapy for patients with NSCLC and common activating mutations of EGFR. Afatinib, an irreversible EGFR, HER2, and HER4 inhibitor, has recently been approved at the dose of 40 mg daily as front-line treatment for advanced NSCLC with common EGFR-activating mutations.Areas covered: The review analyzes the pharmacodynamics, pharmacokinetics, safety, and clinical efficacy of afatinb in NSCLC. This irreversible TKI was initially investigated in EGFR-unselected patients who progressed after TKIs, but the subsequent observation of its major activity against exon 19 mutant determined its indication in common EGFR mutations. Several Phase I to Phase III studies explored the role of afatinib in different settings of patients.Expert opinion: Afatinib showed efficacy as a front-line treatment in patients with EGFR common mutations. Currently, no statistically significant differences between afatinib, gefitinib, and erlotinib have been detected, as they all improve progression-free survival, disease control rate, and control of symptoms in NSCLC EGFR mutant patients; the pooled analysis of LUX-Lung 3 and 6 data in patients harboring Del19 is the only demonstration of a statistical improvement in overall survival with afatinib.

Original languageEnglish
Pages (from-to)1357-1364
Number of pages8
JournalExpert Opinion on Orphan Drugs
Volume3
Issue number11
DOIs
Publication statusPublished - Nov 2 2015

Keywords

  • Afatinib
  • EGFR mutations
  • Irreversible tyrosine kinase inhibitors
  • NSCLC
  • Pivotal trials
  • Targeted therapies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Fingerprint Dive into the research topics of 'Afatinib for the treatment of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this